Table 3.

Uni‐ and multi‐variable linear regression analyses for the association with the desmoplastic HGP in a combined cohort of patients with available genetics data.

	Univariable		Multivariable (n = 333)
	β (95% CI)	P value	β (95% CI)	P value
Primary tumour location, right‐ versus left‐sided or rectal	−0.61 (−4.64–3.43)	0.767	2.46 (−6.57–11.49)	0.593
Primary tumour T‐stage, (y)pT 0–4*	−1.91 (−4.41–0.60)	0.136	−1.77 (−6.88–3.33)	0.495
Primary tumour nodal status, (y)pN 0–2*	−3.71 (−5.99–−1.43)	0.001	−8.59 (−13.76–−3.42)	0.001
APC, mutant versus wildtype	0.82 (−7.40–9.03)	0.845	0.81 (−10.14–11.75)	0.885
KRAS, mutant versus wildtype	3.70 (−1.02–8.41)	0.124	−0.55 (−8.38–7.28)	0.890
NRAS, mutant versus wildtype	8.83 (−3.65–21.31)	0.165	5.33 (−15.06–25.73)	0.607
BRAF, mutant versus wildtype	3.31 (−10.09–16.71)	0.628	5.45 (−15.41–26.31)	0.608
MSI, MSI versus MSS	20.82 (1.89–39.75)	0.031	39.97 (13.59–66.34)	0.003
Disease‐free interval, months*	−0.26 (−0.35–−0.17)	<0.001	−0.26 (−0.54–0.03)	0.076
Number of CRLM*	1.21 (0.52–1.91)	<0.001	1.66 (0.15–3.17)	0.031
Diameter of largest CRLM, cm*	−2.23 (−2.85–−1.61)	<0.001	−1.34 (−2.96–0.27)	0.103
Preoperative CEA level, 100 μg/l*	−0.09 (−0.35–0.17)	0.479	0.31 (−0.15–0.77)	0.191
Preoperative chemotherapy, yes versus no	22.00 (18.68–25.32)	<0.001	19.83 (10.85–28.82)	<0.001

MSS, microsatellite stable.

^*Entered as continuous variable.